BMJ

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials

Objective To compare the efficacy and safety of brodalumab, an interleukin-17 receptor subunit A inhibitor, with placebo, in patients with psoriatic arthritis (PsA). Results 962 patients were ...
Healio

Deucravacitinib demonstrates durable response in psoriatic arthritis

Please provide your email address to receive an email when new articles are posted on . CHICAGO — The novel, oral tyrosine kinase 2 inhibitor deucravacitinib yielded durable ACR20 response rates ...
Healio

Rosnilimab achieves T-cell depletion, ‘clinical proof of concept’ in rheumatoid arthritis

Please provide your email address to receive an email when new articles are posted on . Rosnilimab depletes pathogenic T cells in patients with RA. Patient-reported data showed clinically important ...
Nature

Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs—from bench to bedside

The chronic nature of rheumatoid arthritis (RA) means that patients require drug therapy for many years. Many RA patients, however, have to discontinue treatment because of drug-related toxic effects, ...
rmdopen.bmj

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study

Background In SELECT-PsA 1, a randomised double-blind phase 3 study, upadacitinib 15 mg and 30 mg were superior to placebo and non-inferior to adalimumab in ≥20% improvement in American College of ...